C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.
about
Debate: When should we intervene in unstable angina - Time for an old look?A new scoring system to stratify risk in unstable anginaFluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromesCoagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparinCritical appraisal of C-reactive protein throughout the spectrum of cardiovascular diseaseAcute coronary syndromes: diagnosis and management, part IRecent advances in ischaemic heart disease.The puzzle of depression and acute coronary syndrome: reviewing the role of acute inflammation.The impact of platelet function or C-reactive protein, on cardiovascular events after an acute myocardial infarctionConcurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.Variation in high-sensitivity C-reactive protein levels over 24 hours in patients with stable coronary artery disease.Inflammation, the acute phase response and atherosclerosis.Management of unstable angina based on considerations of aetiologyHigh-sensitivity C-reactive protein as a predictor of cardiovascular events after ST-elevation myocardial infarction.Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis.Preoperative C-reactive protein predicts long-term mortality and hospital length of stay after primary, nonemergent coronary artery bypass grafting.Chemokines CCL3/MIP1α, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes.Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) III.Role of biomarkers in risk stratification of acute coronary syndromeQuantitative proteomics for cardiac biomarker discovery using isoproterenol-treated nonhuman primates.Ceruloplasmin is a better predictor of the long-term prognosis compared with fibrinogen, CRP, and IL-6 in patients with severe unstable angina.Inflammatory bio-markers and cardiovascular risk prediction.High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment.Statins and C-reactive protein: considering a novel marker of cardiovascular risk.Critical review of unstable angina and non-ST elevation myocardial infarctionEffect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery.Simultaneous consideration of multiple candidate protein biomarkers for long-term risk for cardiovascular events.Effects of niacin on atherosclerosis and vascular function.Repetitive element DNA methylation and circulating endothelial and inflammation markers in the VA normative aging studyExaggerated neurobiological sensitivity to threat as a mechanism linking anxiety with increased risk for diseases of agingInflammatory and thrombotic mechanisms in coronary atherosclerosisIncreased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin THelper T cells and atherosclerosis: the cytokine webPharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions.Copeptin testing in acute myocardial infarction: ready for routine use?C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?Cumulative risk assessment in unstable angina: clinical, electrocardiographic, autonomic, and biochemical markersModern risk stratification in coronary heart disease.
P2860
Q24792342-E72E2A84-7034-4D85-BAA7-A6896CCBAB54Q24799274-672CE520-D51D-49BB-AC9A-FEDA2CAC11CAQ24806340-E2B1F5AD-3161-4FAD-92B7-A266C32CC308Q28167462-4BC9BDEC-A604-4BF5-A430-8ABB2096A26DQ28208874-EEB9A8BB-543E-4E6A-8E22-95CB8E3B4BDDQ28219483-044CB996-BEA0-4EB5-8DFB-0099C82F1E05Q30490718-A22FCE74-CF4A-45B5-8E26-92A59B0A9257Q30912640-1337722E-DDA9-4587-9203-A64A020D49F2Q33351796-C52FD2B9-E7D7-407C-83B4-5180C4F01F01Q33479327-77E86481-71E7-4D44-B458-48F77593F7ACQ33691730-11119732-585D-40E0-A79E-DA09D0A443EFQ33693211-54616836-E406-496C-AD01-4F23050D0928Q33694694-7E646B8D-7D68-411C-9503-FC4C769CF169Q33723966-182CBCC2-2A7E-4A36-BE3A-BC9415C06E26Q34020672-A9D3A19D-A1AF-47A8-9D44-C0F6593C2927Q34362340-4C57BAF4-CEF7-4CF7-9111-3DEA78DDACD0Q34398697-BF04C8F2-3762-4DDB-AEF2-9134643C1AC5Q34430115-67188C8E-E372-44EF-92EF-FB03DE8CE76DQ34445660-8E911ABD-8CB4-4743-9ACF-1258D5F75AF0Q34520790-5C528808-DAAD-4E95-A483-EC1AAAFF2267Q34530136-F1DEC2D6-C7B7-441B-8622-08FE18D99EAFQ34669434-EDA0645F-171B-46C6-B6A8-34B5CF821853Q34767602-5E85A720-9E05-4876-AA88-5EB4EBE55B3CQ34941391-AA415F1C-1E70-4DC1-9B1E-FD3607ED904DQ34973446-5519E2AD-60D2-422A-8B9B-72EFA06A83A7Q34989692-0977276C-B4C3-48CE-BB54-7FABEB55341AQ35037630-B91CAC2A-2F5E-4C6B-B01A-2C65059467D4Q35049195-04AA0FAC-78D9-4CC8-9B27-399EA6A20D08Q35102374-EE941A92-C503-4351-A584-AB588AF78270Q35132366-7F2AD792-F363-43DE-9248-E68F748665AAQ35163311-EAB0FBF5-38EA-4E84-B314-8D3E6B393536Q35180746-2899F001-7D71-4B89-AAD5-58CB9E48EB6AQ35201247-3EFDFA9C-004D-472F-8404-5C15CF1577E4Q35379064-694A8A41-AB9C-4FD2-8D10-ED786C9B77EAQ35523321-BB763796-4892-40A3-B80A-5A3300FD106BQ35549761-8E7A0D94-C581-4247-B163-78B275A10359Q35556651-531AC78A-5237-423C-887E-00BF2D149AD0Q35558793-B8436029-59D9-4B56-9AC7-8F9792C4BD6FQ35580755-C7ABCD0B-483F-491D-A538-3BCA63AABA92Q35581714-D76AD434-490D-4D26-9DC3-28F5E2F83C3C
P2860
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
C-reactive protein is a potent ...... ysis in Myocardial Infarction.
@en
C-reactive protein is a potent ...... ysis in Myocardial Infarction.
@nl
type
label
C-reactive protein is a potent ...... ysis in Myocardial Infarction.
@en
C-reactive protein is a potent ...... ysis in Myocardial Infarction.
@nl
prefLabel
C-reactive protein is a potent ...... ysis in Myocardial Infarction.
@en
C-reactive protein is a potent ...... ysis in Myocardial Infarction.
@nl
P2093
P1476
C-reactive protein is a potent ...... ysis in Myocardial Infarction.
@en
P2093
P304
P356
10.1016/S0735-1097(98)00136-3
P407
P577
1998-06-01T00:00:00Z